ISSN: 0973-7510

E-ISSN: 2581-690X

Review Article | Open Access
Pradeep Kumar1, Manish Kumar Verma2*, Rachna Sharma3, Rohit Agrawal4, Shashi Prabha Singh2, Anoop Jaiswal5, Om Prakash2, Navneet Soni6, Poonam Verma7, Areena Hoda Siddiqui8, Shalabh Gupta9
and Preeti Sharma2
1Department of Biochemistry, ASJSATDS Medical College, Fatehpur – 212 601, Uttar Pradesh, India.
2Department of Biochemistry, Santosh Medical College, Santosh Deemed to be University, Ghaziabad – 201 009, Uttar Pradesh, India.
3Department of Biochemistry, TSM Institute of Medical Sciences, Lucknow – 226 009, Uttar Pradesh, India.
4Department of Pediatrics, Autonomous State Medical College, Hardoi – 241 121, Uttar Pradesh, India.
5Department of Biochemistry, Moti Lal Nehru Medical College, Allahabad – 211 001, Uttar Pradesh, India.
6Department of Pharmacology, Narsinhbhai Patel Dental College & Hospital, Gujarat – 384 315, India.
7Department of Biotechnology, IFTM University, Moradabad – 244 102, Uttar Pradesh, India.
8Department of Laboratory Medicine, Sahara Hospital, Lucknow – 226 010, Uttar Pradesh, India.
9Department of Surgery, Santosh Medical College, Santosh Deemed to be University, Ghaziabad – 201 009, Uttar Pradesh, India.
Article Number: 7266 | © The Author(s). 2022
J Pure Appl Microbiol. 2022;16(3):1465-1478.
Received: 21 August 2021 | Accepted: 27 April 2022 | Published online: 17 August 2022
Issue online: September 2022

Since its sudden outbreak in December 2019 in Wuhan, A pandemic of SARS-CoV-2 has been announced. Vitamin C is a water-soluble vitamin with anti-oxidant and immunity-boosting properties. Vitamin C acts as a nutritional supplement profoundly impacting the immune response to the second or third wave of the coronavirus disease (COVID-19). Vitamin C efficacy as an adjuvant treatment for inflammation and symptoms associated with COVID-19 infection should be investigated further. This report sheds light on the available information on the current clinical trials and pharmacotherapy related to COVID-19. Information available on Pubmed, EMBASE, Scopus, Web of Science databases and EU clinical trials regarding the use of therapeutic agents in patients with COVID-19 was used to perform analysis. Data was taken from 18 clinical trials available in the U.S. National Library of Medicine. All trials that are active, completed, or in the process of recruiting are included in data. Because of majority of clinical trials are still ongoing, specific results and high-quality clinical evidence are lacking. Before being standardised for use, the protocol must undergo large randomised clinical studies using a variety of existing medications and potential therapies. The pivotal role played by vitamins C in maintaining our immune system, is quite apparent. This review is an attempt to summarize the available information regarding the use of vitamin C as an adjuvant therapy in COVID-19 patients.


Coronavirus Infection, Vitamin C (Ascorbic acid), Antiviral Agents, Severe Acute Respiratory Syndrome

Article Metrics

Article View: 140

Share This Article

© The Author(s) 2022. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.